



Proteomics International

LABORATORIES LTD

ASX Release

27 July 2026

ASX code: PIQ

Quarterly Activities Report - Fourth Quarter FY26

KEY HIGHLIGHTS

Operational Highlights

- Executed on strategic plan announced on 28 April 2026.
 - Completed corporate re-structure to establish streamlined and commercially focused operating team.
 - Executed (post quarter end) a national distribution agreement with Healius Limited subsequent to quarter end for the Promarker® portfolio in Australia.
 - Healius appointed exclusive Australian pathology distribution partner for an initial term of three years, with an option to extend for a further three years by mutual agreement.
 - Streamlined lab protocols and progressed refinement of Promarker assays.
- Published PromarkerD United States health economics manuscript.
- Secured grant of United States Patent No. 12674806, titled 'Endometriosis Biomarkers', covering methods of diagnosing endometriosis using specific protein biomarkers measured in blood samples and using the results to guide treatment selection.
- Commenced the strategic review of OxiDx to assess potential development, partnership, licensing and other strategic options.
- Renewed Australian laboratory accreditation under ISO 15189 and ISO 17025.

Financial Highlights

- Cash outflows from operations of \$2.08 million for the quarter ended 30 June 2026 (including approximately \$0.46 million one off redundancy and entitlement payments).
- Cash and cash equivalents of \$3.50 million as at 30 June 2026.

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com

Classification: Restricted

Part of the PILL Group

PERTH, AUSTRALIA: Proteomics International Laboratories Ltd (Proteomics International or the Company; ASX: PIQ) today releases its Appendix 4C and quarterly business update for the three months ended 30 June 2026 and subsequent to the period end.

OPERATIONAL UPDATE

Organisational Restructure

[ASX: 17 April 2026] Proteomics International announced a series of organisational and leadership changes as part of the strategic review, to support the Company's transition from a predominantly research driven organisation to a commercially focused diagnostics company. As a result of the restructure, approximately 25% of positions (nine roles) across the organisation were made redundant. This is expected to deliver annualised cost savings of more than \$1 million, strengthening the Company's cash position and supporting continued investment in priority commercial activities.

In addition, as part of the organisational restructure in April, the Company appointed Mr Tim Luscombe as Chief Financial Officer, in addition to his existing role as Company Secretary, and Mr Neville Gardner retired from the Board having served as a Director and Chairman since November 2021.

Commercialisation and Distribution

During the quarter, the Company continued to progress its distributor-led commercialisation strategy for the Promarker® portfolio in Australia and the United States.

Subsequent to quarter end as announced on 22 July 2026, Proteomics International entered into a national distribution agreement with Healius Limited, appointing Healius as the exclusive Australian pathology distribution partner for the Promarker® portfolio.

The agreement has an initial term of three years, with an option to extend for a further three years by mutual agreement. Proteomics International will continue to perform testing through its accredited laboratory infrastructure and provide clinical reporting. Healius will support specimen collection, pathology distribution, referrer engagement and market access through its national network, including more than 2,000 patient collection centres.

Implementation activities have commenced, with phased commercial rollout planned during FY27 following completion of operational, laboratory and information technology integration.

As the Promarker® portfolio is at an early stage of commercialisation, the revenue that may be generated under the distribution agreement cannot be reliably estimated at this time. The Company will update the market on material developments in accordance with its continuous disclosure obligations. The commercial terms of the agreement are confidential.

CEO and Managing Director, David Morris, presented a webinar on 23 July 2026 regarding the agreement. Shareholders and interested parties can access a recording of the webinar [here](#).

PromarkerD

Activity during the quarter focused on reimbursement readiness and supporting evidence generation. The Company's United States health economics manuscript was published in PharmacoEconomics.

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com

Classification: Restricted

Part of the PILL Group

PromarkerEso

Continued refinement of PromarkerEso assay and development of streamlined lab protocols.

PromarkerEndo

Continued PromarkerEndo assay validation and clinical protocols.

Subsequent to quarter end, the United States Patent and Trademark Office granted United States Patent No. 12674806, titled 'Endometriosis Biomarkers', for the Company's PromarkerEndo technology. The granted patent covers methods of diagnosing endometriosis using specific protein biomarkers measured in blood samples and using the results to guide treatment selection. The patent strengthens the Company's intellectual property position in the world's largest healthcare market and is expected to extend until March 2041, subject to maintenance requirements.

Patent protection for the technology has now been granted in the United States and Japan, while applications continue to be pursued in other key jurisdictions.

OxiDx

The Company commenced a strategic review of OxiDx during the quarter. The review is assessing potential business models, product development requirements, partnership and licensing opportunities, and other strategic options. Further investment will be considered having regard to commercial potential, capital requirements and alignment with the Company's strategic priorities.

Laboratory, Quality and Regulatory

The Company renewed its Australian laboratory accreditations under ISO 15189 and ISO 17025 following NATA reassessment.

Laboratory and quality activities focused on assay validation, operating procedure improvements, workflow consistency and preparation for distributor implementation.

FINANCIAL UPDATE

Proteomics International finished the June 2026 quarter with cash and cash equivalents of \$3.5 million, compared with \$5.69 million at 31 March 2026.

Net cash used in operating activities was \$2.08 million for the quarter.

Operating cash flows included:

- Outflows of \$1.09 million for staff and administration and corporate costs.
- Outflows of \$0.87 million for research and development.
- Outflows of \$0.29 million for product manufacturing, operating, advertising and marketing costs.

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com

Classification: Restricted

Part of the PILL Group

The net operating cash outflows included approximately \$0.46 million of non-recurring redundancy and entitlement payments because of the organisational restructure announced in April 2026.

Based on the cash balance at quarter end and net cash used in operating activities, the Company had approximately 1.7 quarters of funding available as at 30 June 2026, as reported in item 8.5 of the accompanying Appendix 4C.

Payments to Related Parties and Their Associates

In accordance with Listing Rule 4.7C, payments to related parties and their associates included in item 6.1 of the Appendix 4C totalled \$208,000 and comprised directors' fees, executive remuneration and superannuation paid under existing employment and service arrangements.

This announcement has been authorised for release by the Board of Proteomics International Laboratories Ltd.

-ENDS-

For further information please contact

Dr James Williams

Chairman

Proteomics International Laboratories Ltd

T: +61 8 9389 1992

E: enquiries@proteomicsinternational.com

Mr David Morris

CEO & Managing Director

Proteomics International Laboratories Ltd

T: +61 8 9389 1992

E: enquiries@proteomicsinternational.com

About Proteomics International Laboratories Ltd

Proteomics International Laboratories Ltd (ASX: PIQ) is a medical technology company specialising in proteomics and precision diagnostics. The Company develops and commercialises blood-based tests designed to support earlier and more precise diagnosis and risk assessment.

Proteomics International has established accredited laboratory facilities in Australia and the United States and is headquartered in Perth, Western Australia.

Forward-Looking Statements

This announcement may contain forward-looking statements regarding future events and the future performance of Proteomics International.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied.

These statements are based on information available to the Company as at the date of this announcement and are not guarantees of future performance. Except as required by law or the ASX Listing Rules, the Company undertakes no obligation to update any forward-looking statements.

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com

Classification: Restricted

Part of the PILL Group

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Proteomics International Laboratories Ltd

ABN

78 169 979 971

Quarter ended ("current quarter")

30 June 2026

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (12 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	128	2,247
1.2 Payments for	(866)	(3,633)
(a) research and development		
(b) product manufacturing and operating costs	(282)	(1,628)
(c) advertising and marketing	(4)	(1,073)
(d) leased assets	-	-
(e) staff costs	(886)	(3,517)
(f) administration and corporate costs	(208)	(928)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	53	240
1.5 Interest and other costs of finance paid	(23)	(41)
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	2,687
1.8 Other (GST)	-	-
1.9 Net cash from / (used in) operating activities	(2,088)	(5,646)
2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	-	(2,066)
(d) investments	-	-
(e) intellectual property	-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (Security deposits)	-	-
2.6	Net cash from / (used in) investing activities	-	(2,066)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	7	733
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	(133)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (leases)	(112)	(425)
3.10	Net cash from / (used in) financing activities	(105)	175

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	5,693	11,037
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(2,088)	(5,646)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	(2,066)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(105)	175
4.5	Effect of movement in exchange rates on cash held	-	-
4.6	Cash and cash equivalents at end of period	3,500	3,500

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	530	1,158
5.2	Call deposits	2,970	4,534
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	3,500	5,693

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	208
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		
The amount at 6.1 includes Director fees for Non-Executive Directors and salary (including superannuation) for the Managing Director.		

7.	Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	Total financing facilities	-	-
7.5	Unused financing facilities available at quarter end		-
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		

8.	Estimated cash available for future operating activities	\$A'000
8.1	Net cash from / (used in) operating activities (item 1.9)	(2,088)
8.2	Cash and cash equivalents at quarter end (item 4.6)	3,500
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	3,500
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1)	1.7
	<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1	Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
	Answer: No, the June quarter included non-recurring redundancy costs and entitlements payments of approximately \$462,000 as a result of the organisational restructure. If these costs are excluded from the calculation above the Company has greater than two quarters cash per the calculation used in section 8.5. The Company also expects to receive a refund from the Research and Development Tax Incentive for FY26 in H1 of FY27.	
8.6.2	Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
	Answer: The Company regularly reviews its capital position and funding needs and is actively evaluating potential funding opportunities to support its operations and strategic initiatives. These opportunities may include a range of capital management and financing alternatives. While discussions and assessments remain ongoing, the Company believes there is a reasonable prospect of securing additional funding should it be required.	

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: Yes. As announced to the market in April 2026 the Company undertook an organisational restructure which will result in a significant reduction in annualised expenditure.

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

27 July 2026

Date:

Board of Directors

Authorised by:
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.